Irrus Investments
VC Fund
Limerick, Ireland
Irrus Investments is a VC fund in Limerick focused on Health Care and Medical Device. Irrus Investments will invite you to present and discuss the company details.
- Total investments:
- 34
- Last investment:
- Lead investor:
- 18%
Last updated:
For AI agents: llms.txt
Industries Irrus Investments invests in
Stages Irrus Investments invests in
Countries Irrus Investments invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
2 more contacts available
Round size
- Seed
- $713k–$4.7M
- Venture - Series Unknown
- $1.2M–$24M
Investment Focus
Industry
- Health Care 9 (26%)
- Medical Device 9 (26%)
- Biotechnology 7 (21%)
- Medical 6 (18%)
- Health Diagnostics 4 (12%)
Stage
- Seed 14 (41%)
- Venture - Series Unknown 6 (18%)
- Funding Round 4 (12%)
- Series A 3 (9%)
- Series B 2 (6%)
Country
- Ireland 18 (53%)
- Sweden 2 (6%)
- United States 1 (3%)
- United Kingdom 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Emily Ryan
Executive Director
|
Executive Director | Total investments: 3 | Find email | |
|
Leonard Patrick Kiely
Co-Founder
|
Co-Founder | Total investments: 0 | Find email | |
|
Mike Ryan
Director
|
Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Vertigenius
|
Vertigenius designs and deploys customized exercises using an easy-to-use clinician portal and even uses a Vertigenius head sensor to consult and manage patients with dizziness and imbalance. | $3M / Venture - Series Unknown / Apr 08, 2026 | |
Novus Diagnostics
|
Novus Diagnostics are developing a revolutionary sample-to-answer sepsis diagnostic device that can rapidly detect and classify pathogens in whole blood. | $4.7M / Seed / Jan 15, 2025 | |
Deciphex
|
Founded in 2017, Deciphex aims to transform diagnostic workflows through AI-powered digital pathology to improve patient outcomes worldwide. Its two flagship platforms target distinct markets: Diagnexia connects global subspecialty pathologists for rapid diagnostics and backlog reduction, while Patholytix accelerates drug development throughoptimized preclinical safety assessments. By automating routine tasks, these platforms enable pathologists to focus on complex cases while delivering faster, more reliable diagnoses. Through this combination of AI innovation and clinical expertise, Deciphex is advancing both healthcare delivery and therapeutic development. | $32.1M / Series C / Jan 07, 2025 | |
Bounce Insights
|
Bounce Insights is a digital consumer research platform. It provides a direct link between brands and any consumer they needed to speak to by maintaining a community of active, engaged respondents on their mobile app. | $4.5M / Seed / Dec 04, 2024 | |
Ovagen
|
Ovagen is a biotechnology company that has developed the process of producing germ free (GF) chicken eggs and GF birds in commercial quantities for use primarily in the pharmaceutical industry. Ovagen can also provide a Contract Research Service and has extensive expertise in SPF poultry & rodent housing & husbandry, in specific poultry& rodent research technologies to GMP standards and in avian transgenics. | $2.2M / Series A / Oct 29, 2024 | |
SymPhysis Medical
|
SymPhysis Medical's goal is to develop innovative technologies that treat a range of chronic diseases, putting the patient experience at the forefront of our design solutions to improve quality of life.About SymPhysis MedicalSymPhysis Medical's emergent technology, releaze, is a drainage technology to treat a common complication oflate-stage cancers, malignant pleural effusion (MPE). MPE causes significant shortness of breath and chest pain in up to 15% of patients with cancer. | $2.4M / Venture - Series Unknown / Oct 07, 2024 | |
CroíValve
|
CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation | $16M / Series B / Aug 07, 2024 | |
|
SymPhysis Medical
|
SymPhysis Medical's goal is to develop innovative technologies that treat a range of chronic diseases, putting the patient experience at the forefront of our design solutions to improve quality of life.About SymPhysis MedicalSymPhysis Medical's emergent technology, releaze, is a drainage technology to treat a common complication oflate-stage cancers, malignant pleural effusion (MPE). MPE causes significant shortness of breath and chest pain in up to 15% of patients with cancer. | $1.7M / Seed / Dec 21, 2023 | |
FeelTect
|
FeelTect’s technology, Tight Alright, is a pressure sensing, connected-health device for measuring and monitoring sub-bandage pressure during compression therapy, primarily for the millions of people worldwide with venous leg ulcers (VLUs). Compression is a proven therapy for VLUs, however if it’s applied too loose, it’s ineffective, and if it’stoo tight, it’s dangerous. | $1.6M / Dec 20, 2023 | |
|
FeelTect
|
FeelTect’s technology, Tight Alright, is a pressure sensing, connected-health device for measuring and monitoring sub-bandage pressure during compression therapy, primarily for the millions of people worldwide with venous leg ulcers (VLUs). Compression is a proven therapy for VLUs, however if it’s applied too loose, it’s ineffective, and if it’stoo tight, it’s dangerous. | $1.6M / Seed / Dec 20, 2023 | |
| See all 34 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Irrus Investments invest in?
Irrus Investments invests primarily in Health Care, Medical Device and Biotechnology startups, most often at Seed and Venture - Series Unknown stage. Most of the 34 investments tracked by Shizune back companies in Ireland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Irrus Investments's check size?
Irrus Investments typically joins rounds of $713k–$4.7M at Seed and $1.2M–$24M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Irrus Investments participates in.
How do I contact Irrus Investments?
Public channels for Irrus Investments include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Irrus Investments?
The team at Irrus Investments includes Emily Ryan (Executive Director), Leonard Patrick Kiely (Co-Founder) and Mike Ryan (Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
